Pathways to Safe Medicines (WP3188)

7 - 9 June 2023

Wilton Park, Wiston House, Steyning, West Sussex, BN44 3DZ

Wed

07

Jun

15:00 - 16:00 Participants arrive. Tea and coffee on arrival

16:00 - 16:15

Welcome and introduction

Aisling Conboy
Programme Director, Wilton Park, London, United Kingdom

Thomas Woods (Tom)
Chairman, Wilton Park USA Foundation, Washington DC, United States of America

Moji Adeyeye
Director General , National. Agency for Food and Drug Administration and Control, Abuja, Nigeria

16:15 - 18:00

1. A Decade in the Battle Against Falsified Medicines

Health commodity supply chains remain threatened, lacking transparency and traceability, vulnerable to illicit products. What is the challenge in lower- and middle-income countries? Has the scope of the concern changed during and after the global pandemic? How do illicit health products threaten patients today?

Karen Kramer
Senior Drug Control and Crime Prevention Officer, United Nations Office on Drugs and Crime (UNODC), Vienna, Austria

Cindy Buckley
Assistant Director Illicit Markets, INTERPOL, Lyon, France

18:00 Reception followed by dinner

Thu

08

Jun

06:30 **OPTIONAL - Chanctonbury Ring Walk**

Optional walk from Wiston House to Chanctonbury Ring, a prehistoric hill fort on the South Downs. Approximately 4 miles with a steep climb , taking around 1 hour 30 mins - 2 hours.

Required - walking shoes/boots as may be muddy.

08:00 - 09:00 Breakfast

09:15 - 10:30

2. National Authorities Together with Regional Coordination

Lower- and middle-income countries continue to face the toughest challenge when it comes to illicit medicines flows. As the front-line entities battling to protect patients, what role can, and should various national agencies play? What support could regional and sub-regional coordination provide?

Deon Poovan
Senior Manager - Inspectorate and Regulatory Compliance, South Africa Health Products Regulatory Authority, Pretoria, South Africa

Parthasarathi Gurumurthy
Director, Pharmacovigilance and Clinical Trials, Botswana Medicines Regulatory Authority (BoMRA), Gaborone, Botswana

---

10:30 - 11:15 Photograph followed by tea/coffee

11:15 - 13:00

3. Medicines traceability: tested tool for patient safety

The Lagos Call to Action generated consensus around global standards for traceability across Africa. How can we reinvigorate action and help Africa shorten its journey? As traceability is driven at the national level, what role must regulators play? Private sector? Donor agencies? What represents an achievable timeframe and what are the benefits to all stakeholders?

Geraldine Lissalde Bonnet
Vice-President Healthcare, GS1 , Brussels, Belgium

Pascal Aulagnet
Director Regulatory and Market Engagement, Pfizer Pharmaceuticals, Amboise, France

Lindabeth Doby
Senior Digital Supply Chain Advisor, United States Agency for International Development (USAID), Washington, DC, United States of America

---

13:00 - 14:00 Lunch

13:00 - 13:15 Facilitators' briefing (in the Conference room)

14:00 - 15:00 Free time / optional garden tour

15:00 - 16:30

4. Risk Mitigation

Longer term interventions like medicines traceability require time to build and do not represent a panacea. What additional risk mitigation measures must be present in order to protect patients? What must happen at the national level and what regional efforts can help mitigate the risk of supply chain vulnerabilities and the presence of falsified medicines in both the public and private supply chains? How do we build consensus around resilient supply chain solutions supported by the public and private sectors?

Tony Zook
AVP Global Security, Merck & Co., Inc, West Point, United States of America

Xavier Tomsej
Supply Chain Lead, Office of the Assistant Administrator for Global Health, United States Agency for International Development (USAID), Washington, DC, United States of America

Stanislas Barro
Global Head Anti-Falsified Medicines, Novartis, Basel, Switzerland

16:30 - 17:00 Tea/coffee

17:00 - 18:30

5. Breakout session. Public private collaboration: a multifaceted approach to combatting falsified medicines

Global standards for traceability represent tangible public and private collaboration for patient safety. How will the public and private sector map strategic priorities that meet supply chain integrity goals and enhance patient protection? What other partnerships, tools or interventions can enhance patient safety? What roles can and should various national authorities play, private sector, and donor agencies? What mechanism can keep these efforts on track and help maintain coordinated focus?

19:00 Reception followed by dinner

Fri

09

Jun

08:00 - 09:00 Breakfast and checkout

09:15 - 10:00

6. Feedback from breakout groups: putting forward practical proposals

10:00 - 11:00

7. Illicit health products and cooperation on enforcement activities

Supply chain integrity measures are essential but must be accompanied by cooperation with national and international enforcement agencies. How can we improve efforts to work across organizations and stakeholders to better coordinate actions that counter illicit behaviour? Is there scope for enhanced investigations and enforcement that disrupt and dismantle criminal networks that endanger patients? How will we ensure ongoing cross-cutting cooperation?

Gbenga Fajemirokun
SPECIAL ASSISTANT TO DIRECTOR GENERAL, National Agency for Food and Drug Administration and Control (NAFDAC), LAGOS, Nigeria

11:00 - 11:15 Tea/coffee

11:15 - 11:25

8.Evaluation Survey

Completion of online survey

11:25 - 13:00

9. Mapping a pathway to success and next steps

Combatting illicit health products in LMICs will be an ongoing and evolving process. Major initiatives like national traceability systems require concerted efforts and multi-year commitments to build and sustain. As we build a consensus agenda for a pathway to safe medicines, what tangible steps will guide and shape collective efforts over the next 12-18 months?

What are the immediate next steps and who will take them? How do we strengthen linkages between stakeholders, from law enforcement to public health supply chain experts to national regulatory agencies? How will we stay on track and keep stock of the diverse contributions of each organisation? How can efforts be continually updated, coordinated and sustained?

13:00	Lunch
14:00	Participants depart